Immunochemical studies of mucin-type glycoproteins

粘蛋白型糖蛋白的免疫化学研究

基本信息

  • 批准号:
    04454596
  • 负责人:
  • 金额:
    $ 4.1万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
  • 财政年份:
    1992
  • 资助国家:
    日本
  • 起止时间:
    1992 至 1994
  • 项目状态:
    已结题

项目摘要

To reveal the characteristic structures of mucins, mucin-specific monoclonal antibodies, MSW 113, MLS 102 and MLS 128, have been established. Using MSW 113, as an immunoaffinity agent, oligosaccharides have been isolated from human colostrum, all of which have the sialyl-Le^a determinant in linear and branched structures. Some of the oligosaccharides have the sialyl-Le^x determinant in addition to the sialyl-Le^a in the same molecule. These indicate that MSW 113 have a broad binding specificity.MSW 113 is in fact superior to NS 19-9, recognizing sialyl-Le^a structure specifically, in reacting with oligosaccharides having a variety of structures, which made MSW 113 a useful reagent to detect cancer antigens in sera of patients.Epitopes for MLS 102 and MLS 128, respectively, have been determined. MLS 102 is an anti-sialyl Tn antibody. From ovine submaxillary mucin (OSM), glycopeptides with a cluster structure, composed of Sia-GalNAc-Ser/Thr, have been isolated. After the removel of sialic acid, the glycopeptides turned out to be the epitope for MLS 128, an anti-Tn antibody. The cluster structure composed of three or four consecutive sequences of GalNAc-Ser/Thr was initially found in OSM,but similar clusters have then been found in Tn-glycophorin A from Tn erythrocyte and leukosialin from a T-lymphoid cell, Jurkat.Sialyl Tn and Tn antigens have been regarded as tumor marker. In fact, MLS 102 and MLS 128 are effective in staining histochemically cancer tissues, thus being potentially candidates for in vivo imaging agents for cancer patients.Mucins were isolated from cancer cells and pleural fluids from cancer patients and their carbohydrate moieties were analyzed. Like OSM,these mucins express at least both sialyl Tn and Tn antigens. The factors which determine the co-expression of these two antigens remain unknown, since the co-expression occurs in the circumstance where sugar transferases including sialyl transferase occur.
为了揭示粘蛋白的特征结构,已经建立了粘蛋白特异性单克隆抗体MSW 113、MLS 102和MLS 128。使用MSW 113作为免疫亲和剂,已从人初乳中分离出寡糖,所有这些寡糖都具有线性和分支结构的唾液酸-Le ^a决定簇。一些寡糖在同一分子中除了唾液酸-Le ^a之外还具有唾液酸-Le ^x决定簇。MSW 113与多种结构的寡糖反应,特异性识别唾液酸-Le_a结构,是一种上级NS 19-9的特异性结合抗原的试剂,可用于检测患者血清中的癌抗原,并测定了MLS 102和MLS 128的抗原表位。MLS 102是抗唾液酸Tn抗体。从绵羊颌下粘蛋白(OSM)中分离到了一种由Sia-GalNAc-Ser/Thr组成的簇状结构的糖肽。在去除唾液酸后,糖肽被证明是抗Tn抗体MLS 128的表位。最初在OSM中发现了由三个或四个连续的GalNAc-Ser/Thr序列组成的簇结构,但随后在Tn红细胞的Tn血型糖蛋白A和T淋巴细胞的白唾液酸中发现了类似的簇结构。唾液酸Tn和Tn抗原被认为是肿瘤标志物。事实上,MLS 102和MLS 128在组织化学染色癌组织中是有效的,因此是用于癌症患者的体内成像剂的潜在候选物。与OSM一样,这些粘蛋白至少表达唾液酸化Tn和Tn抗原。决定这两种抗原的共表达的因素仍然未知,因为共表达发生在糖转移酶(包括唾液酸转移酶)发生的情况下。

项目成果

期刊论文数量(52)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
H.Nakada,et al.: "Cancer-associated glycoproteins defined by a monoclonal antibody,MLS 128,recognizing the Tn antigen." Biochem.Biophys.Res.Commun.187-1. 217-224 (1992)
H.Nakada 等人:“由单克隆抗体 MLS 128 定义的癌症相关糖蛋白,可识别 Tn 抗原。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
H.Nakada, M.Inoue, N.Tanaka, N.Wakamiya and I.Yamashina.: "Expression of the T antigen on a T-lymphoid cell line, SupT1 cells." Glycoconjugate Journal. (in press).
H.Nakada、M.Inoue、N.Tanaka、N.Wakamiya 和 I.Yamashina.:“T 抗原在 T 淋巴细胞系 SupT1 细胞上的表达。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
山科郁男、中田 博他3名: "Expression of the Tn antigen on a T-lymphoid cell line,SupTl cells" Glycoconjugate Journal. (in press).
Ikuo Yamashina、Hiroshi Nakata 和其他 3 人:“Tn 抗原在 T 淋巴细胞系、SupT1 细胞上的表达”糖复合物杂志(正在出版)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
山科郁男、中田 博他2名: "Coexpression of cancer-associated carbohydrate antigens Tn and sialyl Tn" Glycoconjugate Journal. 11. 262-265 (1994)
Ikuo Yamashina、Hiroshi Nakata 和其他 2 人:“癌症相关碳水化合物抗原 Tn 和唾液酸 Tn 的共表达”《糖结合杂志》11. 262-265 (1994)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
G.Ohshio, H.Toshioka, T.Manabe, H.Sakahara, H.Yamabe, M.Imamura, M.Inoue, N.Tanaka, H.Nakada and I.Yamashina.: "Expression of sialosyl-Tn antigen (monoclonal antibody MLS 102 reactive) in normal tissues and malignant tumors of the digestive tract." J.Canc
G.Ohshio、H.Toshioka、T.Manabe、H.Sakahara、H.Yamabe、M.Imamura、M.Inoue、N.Tanaka、H.Nakada 和 I.Yamashina.:“唾液酸基 Tn 抗原的表达(单克隆)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMASHINA Ikuo其他文献

YAMASHINA Ikuo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMASHINA Ikuo', 18)}}的其他基金

Studies on production of a thrombin-like snake venom enzyme using a recombinant DNA
利用重组DNA生产类凝血酶蛇毒酶的研究
  • 批准号:
    60880020
  • 财政年份:
    1985
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research

相似海外基金

Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Research Grant
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
STABLE CLONE PRODUCTION FOR ANTI-EBV MONOCLONAL ANTIBODIES
抗 EBV 单克隆抗体的稳定克隆生产
  • 批准号:
    10941239
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Development of cancer-specific monoclonal antibodies to the Eph receptor and analysis of their recognition mechanisms
Eph受体癌症特异性单克隆抗体的研制及其识别机制分析
  • 批准号:
    22KJ0297
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Enabling Subcutaneous Delivery of Therapeutic Monoclonal Antibodies via Hydrogel Microparticles
通过水凝胶微粒皮下输送治疗性单克隆抗体
  • 批准号:
    10761250
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease
优化用于预防和治疗 HSV 疾病的单克隆抗体的生成
  • 批准号:
    10717320
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Probing in situ higher order structures of monoclonal antibodies at water-air and water-oil interfaces via high-field nuclear magnetic resonance spectroscopy for viral infections
通过高场核磁共振波谱技术在水-空气和水-油界面原位探测单克隆抗体的高阶结构以检测病毒感染
  • 批准号:
    10593377
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ
TO6 - 生成针对人类和小鼠 COLQ 的单克隆细胞系、单克隆抗体和标记单克隆抗体
  • 批准号:
    10953997
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Exploration for determinant of PK for monoclonal antibodies targeting antigen/receptor expressed on tumor cells
探索针对肿瘤细胞上表达的抗原/受体的单克隆抗体的 PK 决定因素
  • 批准号:
    23K06216
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SBIR Phase I: Generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies
SBIR I 期:产生直接活性的 CD19 单克隆抗体,用于治疗 B 细胞恶性肿瘤
  • 批准号:
    2212682
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了